01—Abstract
Summary
Summary of the 8-K filed April 15, 2024. Cited figures are marked; the original filing is the authoritative source.
Omega Healthcare Investors, Inc. filed this Current Report to disclose that on April 2, 2024, the District Court for the District of Maryland granted preliminary approval to a proposed settlement of the shareholder derivative action Wojcik v.
Omega Healthcare Investors, Inc., et al., Case No. 1:20-cv-03491. The stipulation of settlement is dated February 22, 2024, and involves plaintiff Robert Wojcik, the Company as nominal defendant, and the named individual defendants. The Court has scheduled a final approval hearing for June 24, 2024, at 2:00 p.m.
Eastern Time. On April 15, 2024, the Company posted the Notice of Proposed Settlement and the Stipulation of Settlement to the Governance section of its investor website, and filed both as Exhibits 99.1 and 99.2. The settlement is non-monetary for the Company.
Its principal term is the adoption of corporate governance reforms relating to diversity, discrimination, race, gender, and social justice, which the Board must implement within sixty days of the Effective Date and maintain for no less than two years. The reforms cover an ESG Steering Committee, a new independent director appointed in 2021, director and senior leadership candidate pool processes, diversity training, and board skills and diversity reporting. Omega's insurers are to pay $850,000a in plaintiff's attorneys' fees and expenses, subject to court approval, and the plaintiff may seek a service award of up to $2,000.
The settlement does not resolve the Stourbridge and Swan derivative actions, which the parties have agreed to address in a separate stipulation. The filing states that the defendants deny all wrongdoing and that the settlement is not an admission of liability. Objections by current shareholders are due June 3, 2024, and the settlement becomes effective only after the judgment is entered and becomes final.
02—Key points
Key Highlights
- Preliminary approval granted April 2, 2024 by the U.S. District Court for the District of Maryland for the settlement of the Wojcik shareholder derivative action.
- Final approval hearing scheduled for June 24, 2024, at 2:00 p.m. Eastern Time.
- Settlement consists of corporate governance reforms on diversity, discrimination, race, gender, and social justice, to be maintained for at least two years after the Effective Date.
- Omega's insurers are to pay $850,000 in attorneys' fees and expenses to plaintiff's counsel, subject to court approval; no common fund or shareholder payment is involved.
- The settlement does not resolve the Stourbridge Action or the Swan Action, which the parties to those cases will address in a separate stipulation.
- Defendants deny all wrongdoing, and the stipulation states it is not an admission of liability.
- Shareholder objections are due June 3, 2024, and the Company posted the Notice and Stipulation to its website on April 15, 2024.
03—Questions
Frequently Asked Questions
Does the settlement require Omega to make a cash payment to shareholders?
No. The filing states that the action is not a class action, there is no common fund, and there is no claims procedure. The settlement results in changes to corporate governance rather than payments to individuals. The only monetary term is the $850,000 in attorneys' fees and expenses, which Omega's insurers are to pay to plaintiff's counsel, subject to court approval.
What corporate governance changes does the settlement require?
The Board must adopt resolutions and amend bylaws, committee charters, and policies within sixty days of the Effective Date, and maintain the reforms for at least two years. The reforms include creating an ESG Steering Committee and charter, appointing a new independent and diverse director in 2021, establishing director and senior leadership candidate processes that include at least two members of underrepresented groups, providing diversity training, and reporting board skills and diversity matrices in proxy statements.
What happens next in the case?
The Court will hold a settlement hearing on June 24, 2024, to decide whether to grant final approval. Shareholders who wish to object must file written objections with the Court and serve counsel by June 3, 2024. The settlement becomes effective only after the judgment is entered and becomes final.
Which claims does the settlement not cover?
The stipulation does not resolve the Other Derivative Actions, namely the Stourbridge Action in the Southern District of New York and the Swan Action in the Baltimore City Circuit Court. The parties to those actions have agreed to enter into a separate stipulation of settlement.
04—Continue